Myriad Genetics (MYGN) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Myriad Genetics (MYGN) has outperformed QuidelOrtho (QDEL) over the past year, losing 45.0% versus a loss of 55.5%. Over five years, MYGN leads with a -86.8% price change compared with -90.3% for QDEL. QuidelOrtho is the larger company by market cap ($928.9 million vs $414.2 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | QDEL |
|---|---|---|
| Share price | $4.33 | $13.55 |
| Market cap | $414.16M | $928.85M |
| 1-day change | +3.10% | +9.15% |
| YTD return | -31.71% | -56.55% |
| 1-year return | -45.03% | -55.46% |
| 5-year return | -86.77% | -90.32% |
| Forward P/E | — | 9.39 |
| EPS (TTM) | $-1.18 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.59 | $35.58 |
| 52-week low | $2.74 | $9.92 |
| Distance from 52-week high | -49.59% | -61.93% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -9.70% | +8.31% |
| Average volume | 2.04M | 1.51M |
| Shares outstanding | 95.65M | 68.58M |
| Employees | 2,700 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QuidelOrtho is about 2.2 times larger than Myriad Genetics by market value ($928.85M vs $414.16M).
- MYGN has outperformed QDEL by 10.4 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
MYGN vs QDEL FAQ
Which is bigger, Myriad Genetics or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $928.85M compared with $414.16M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, MYGN or QDEL?
MYGN returned -45.03% over the past 12 months, compared with -55.46% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.